TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants from Study 110 or Study 111 entering the ivacaftor arm must have completed the assigned study drug treatment duration in the previous study.~* Participants from Study 113 entering the ivacaftor arm must have completed all study related treatments through the Follow-up Visit and met the Study 113 responder criteria during the previous study.~* Participants entering the observational arm must have completed at least 4 weeks of study drug treatment in their previous study (Study 110 or Study 111), must have completed the previous study but do not wish to enroll in the ivacaftor arm, or must have completed the previous study but do not meet the inclusion criteria of the ivacaftor arm.~* Participants of childbearing potential entering the ivacaftor arm must not be pregnant.~* Participants entering the ivacaftor arm must be willing to comply with contraception requirements.~Exclusion Criteria (Ivacaftor Arm Only):~* History of any illness or condition that might confound the results of the study or pose an additional risk in administering ivacaftor to the Participant.~* Use of moderate or strong inhibitors or inducers of cytochrome P450 (CYP) 3A.~* Evidence of cataract or lens opacity at or before the Day 1 Visit.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ivacaftor (Type: EXPERIMENTAL): Participants who received Ivacaftor 150 milligram (mg) tablet and/or Placebo matched to Ivacaftor tablet orally, every 12 hours (q12h) in the previous study VX11-770-110 (Study 110; NCT01614457), VX12-770-111 (Study 111; NCT01614470) or VX12-770-113 (Study 113; NCT01685801); received Ivacaftor 150 mg tablet q12h in this VX12-770-112 (Study 112; NCT01707290) up to 104 weeks.
- Observational (Type: NO_INTERVENTION): Participants who received Ivacaftor 150 mg tablet and/or Placebo matched to Ivacaftor tablet, orally, q12h in the previous Study 110 (NCT01614457) or Study 111 (NCT01614470), were observed (did not receive study drug) in this Study 112 (NCT01707290) for up to 2 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Software Enhancements to the Respironics BiPAP Auto Servo Ventilation (AutoSV) Device

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Pre-Study Inclusion Criteria:~* Age 21-80~* Ability to provide consent~* Documentation of medical stability by investigator~Enrollment Inclusion Criteria:~• Participants who, during the ambulatory polysomnography (PSG) study (Stardust), or in lab Diagnostic PSG demonstrated an Apnea Hypopnea Index (AHI) ≥10 or Central Apnea Index (CAI) ≥5~or~• Participants who previously demonstrated Central sleep Apnea (CSA), with a CAI≥5 on Continuous Positive Airway Pressure (CPAP) titration.~Exclusion Criteria:~* • Participants who are acutely ill, medically complicated or who are medically unstable.~  * Pregnancy (will confirm absence of pregnancy with a urine or serum pregnancy test in women of child bearing potential).~ * Participants in whom PAP therapy is otherwise medically contraindicated.~ * Participants who are unwilling to wear CPAP~ * Participants who are currently prescribed nocturnal oxygen use and are unable to forego oxygen during study nights.~ * Participants with previously diagnosed respiratory failure or respiratory insufficiency and who are known to have chronically elevated arterial carbon dioxide levels while awake (PaCO2 ≥ 45mmHg).~ * Participants who have had surgery of the upper airway, nose, sinus, or middle ear within the previous 90 days.~ * Participants with untreated, non- Obstructive Sleep Apnea (OSA)/CSA sleep disorders, including but not limited to; insomnia, periodic limb movement syndrome, or restless legs syndrome (PLM Arousal Index \> 15).~ * Participants who are unwilling to participate in the study.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Respironics BiPAP autoSV2, Then Respironics BiPAP autoSV3 (Type: ACTIVE_COMPARATOR): Participants will be randomized to receive Respironics BiPAP autoSV2 first and Respironics BiPAP autoSV3 second.
- Respironics BiPAP autoSV3, then Respironics BiPAP autoSV2 (Type: EXPERIMENTAL): Participants will be randomized to receive Respironics BiPAP autoSV3 first and Respironics BiPAP autoSV2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sudden Deafness Treatment Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men/women 18 years and older in good health~* Unilateral sensorineural hearing loss developing within 72 hours (SSNHL)~* Pure Tone Average (PTA) (500, 1000, 2000, 4000 Hz) \>/= 50 dB in the affected ear, with the affected ear \>/= 30 dB worse than contralateral ear in at least one of the four frequencies~* Symmetric hearing prior to onset of SSNHL~* Hearing loss must be idiopathic~* Hearing loss must have occurred within the past 14 days~* Must be able to read or write English or Spanish~Exclusion Criteria:~SYSTEMIC DISEASE~* \>21 days prior oral steroid treatment within preceding 30 days~* History of tuberculosis (TB) or positive PPD~* Insulin-dependent diabetes mellitus~* History of rheumatic disease, e.g., rheumatoid arthritis, scleroderma, lupus, etc.~* Serious psychiatric disease or psychiatric reaction to corticosteroids~* History of heart disease or transient ischemic attacks (TIAs)~* Prior treatment with chemotherapeutic or immunosuppressive drugs~* Pancreatitis~* Active peptic ulcer disease or history of gastrointestinal bleeding~* History of HIV, Hepatitis B or C~* Chronic kidney failure~* Alcohol abuse~* Active shingles~* Severe osteoporosis or non-surgical aseptic necrosis of the hip~OTOLOGIC DISEASE~* Prior history of SSNHL~* History of fluctuating hearing loss~* History of Meniere's disease~* History of chronic ear infection~* History of otosclerosis~* History of ear surgery (except childhood pressure equalization \[pe\] tubes)~* History of congenital hearing loss~* History of trauma immediately preceding onset of SSNHL~* History of syphilitic hearing loss~* History of genetic/hereditary hearing loss~* Skull, facial, or temporal bone anomalies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): Nineteen days of oral prednisone
- 2 (Type: EXPERIMENTAL): Four doses of methylprednisolone sodium succinate delivered by injection to the middle ear over 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Whole Brain Radiotherapy With or Without Temozolomide at Daily Fixed-dose for Brain Metastases Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Karnofsky performance status (KPS) ≥ 50~* Life expectancy ≥ 12 weeks~* Histologically confirmed non lymphomatous solid tumors at primary site~* Brain metastases diagnosed with cranial MRI/CT.~* Extracranial metastases or primary tumor uncontrolled are allowed~* Hemoglobin ≥ 10 g/dl~* Absolute neutrophil count of \> 1500/mm3~* Platelet count of ≥ 100,000/mm3~* Blood urea nitrogen (BUN) ≤ 25 mg/dl,~* Serum creatinin ≤ 1.5 mg/dl~* Serum bilirubins ≤ 1.5 mg/dl,~* Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ≤ twice the upper normal limit~Exclusion Criteria~* Pregnant or breast feeding woman~* History of allergic reaction to iodinated contrast media~* Inability to swallow~* Systemic chemotherapy in previous 3 weeks~* Oral chemotherapy in previous 2 weeks~* Prior surgery, chemotherapy, or radiotherapy for a brain neoplasm~* Meningeal carcinomatosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Whole brain irradiation plus Temozolomide (Type: EXPERIMENTAL): Whole brain irradiation at a dose of 30 Gy in 10 daily fractions over 2 weeks, and a fixed dose of oral Temozolomide, 1h before each fraction of whole brain irradiation, 200 mg on Monday, Wednesday, Friday; 300 mg on Tuesday, and Thursday. Without adjuvant cycles of Temozolomide.
- Whole brain irradiation (Type: ACTIVE_COMPARATOR): Whole brain irradiation at a dose of 30 Gy in 10 daily fractions over 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Leukotriene D4 Nasal Provocation Test in Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with allergic rhinitis accompanied with or without asthma~* positive skin prick test (SPT)~* had no acute upper or lower airway infection 2 weeks prior to study~* no oral or nasal anti-histamines~* no leukotriene receptor antagonists for 1 week~* no oral or nasal and inhaled corticosteroids for 2 weeks~Exclusion Criteria:~* smokers~* a past confirmed history of chronic respiratory disease other than asthma~* other severe systemic diseases (myocardial infarction, malignant tumor, etc.)~* under immunotherapy~* unable to complete the test or had limited understanding~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- leukotriene D4 (Type: EXPERIMENTAL): Nasal provocation test was induced by leukotriene D4 with a stepwisely concentration method (4 mcg/ml, 8 mcg/ml, 16 mcg/ml).
- histamine (Type: EXPERIMENTAL): Nasal provocation test was induced by histamine with a stepwisely concentration method (0.4 mg/ml, 0.8 mg/ml, 1.6 mg/ml, 3.2mg/ml).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cerebral Blood Flow During Hemodialysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult, age ≥ 65 years, HD patients who have been treated with maintenance HD, of which at least 6 patients for a longer period of time (\>1 year).~* Patients must have an arteriovenous fistula without recirculation~* The hemoglobin value must be in the target range (6.2 - 8mmol/l) since at least 1 month~Exclusion Criteria:~* The absence of informed consent~* Diagnosis of dementia, hydrocephalus, history of raised intracranial pressure, significant (\>70%) carotid artery stenosis, end-stage liver disease.~* Actively treated cancer~* Actual hospital admission at timing of HD study session~* MRI incompatible implants in the body or any other contraindication for MRI~* Claustrophobia~* The refusal to be informed of significant carotid artery stenosis or structural brain abnormalities that could be detected during the study.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CBF change during hemodialysis (Type: OTHER): \[15O\]H2O PET-CT scan and NIRS (Invos)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity Study of Insulin Glargine Ezelin vs Lantus in Type 2 Diabetes Mellitus Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women, 18 years old and above~* Diabetes mellitus type 2 patients who has failed an oral hypoglycemic drug products, insulin-naive, disease duration of at least 6 months, inadequate glycemic control (HbA1c \> 7.0 %)~* BMI ranged from 19 - 35 kg/m2~* Consent from patients of childbearing potential to use contraception method throughout the study~* Signed informed consent form~Exclusion Criteria:~* History of diabetic ketoacidosis more than 2 times in the past 1 year~* History of pancreatectomy~* Estimated glomerular filtration rate \<30 mL/min~* Positive ZnT8 Antibody~* Treatment with glucocorticoids, immunodepressant or cytostatics in 60 days before study.~* Any malignant disease, including in medical history~* Drugs and alcohol abuse, including in medical history~* Hipersensitivity to insulin glargine or any excipient of the drugs from medical history~* Mental disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin Glargine Ezelin (Type: EXPERIMENTAL): Drug product Insulin Glargine, Ezelin 100 U/mL (PT Kalbe Farma, Tbk)
- Insulin Glargine Lantus (Type: ACTIVE_COMPARATOR): Insulin Glargine Pen Injector \[Lantus\]

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nuevo Amanecer: Promoting the Psychosocial Health of Latinas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Self-identifies as Latina~* Diagnosed with Stage 0, I, II, or III in the prior month~* Primarily Spanish-speaking, or Spanish monolingual~* Aged 18 or older~* Diagnosed in Alameda, Contra Costa, San Mateo, San Francisco or Santa Clara counties, California.~Exclusion Criteria:~* Previous cancer diagnosis except for non-melanoma skin cancer~* Terminal illness~* Stage IV breast cancer (distant metastasis)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peer Support Program (Type: EXPERIMENTAL): Nuevo Amanecer is the peer support program. Participants receive the peer support program as soon as possible after randomization.
- Wait-list Control (Type: NO_INTERVENTION): Waits six months, and at the end of the six months is offered the option of participating in the peer support program.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir Treatment Simplification Strategy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* HIV positive adults \> or = 19 years of age~* receiving stable therapy including one or two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), in conjunction with a once-daily protease inhibitor (PI) (atazanavir, lopinavir or darunavir) and twice daily raltegravir or once daily dolutegravir~* Virologic suppression for \>6 months, defined as plasma viral load (VL) consistently \< 200 copies/mL with no evidence of prior virologic rebound (VL \> 1000 copies/mL) on the NRTI/PI/Raltegravir regimen, AND VL \< 50 copies/mL at time of study screening~* Estimated glomerular filtration rate (eGFR) \> o r= 70mL/min at screening~Exclusion Criteria:~* Prior documented viral rebound \> 1000 copies/mL on any raltegravir-containing regimen~* Evidence of resistance mutations compromising raltegravir or elvitegravir activity on prior genotypes.~* Evidence of clinically significant resistance to tenofovir on any previous genotype tests: K65R mutation, or 3 or more thymidine-analogue associated mutations (TAMS) compromising tenofovir activity~* Evidence of resistance mutations significantly compromising darunavir activity on any previous genotypic tests~* Current use of any nonnucleoside reverse transcriptase inhibitor (NNRTI)~* Pregnancy or breast-feeding~* Contraindications to tenofovir/FTC, elvitegravir, or cobicistat (e.g. previous significant toxicity, intolerance or drug interactions

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment simplification (Type: EXPERIMENTAL): Open-label darunavir 800mg in conjunction with the co-formulated tenofovir DF/FTC/cobicistat/elvitegravir (Stribild) tablet, both taken together once daily with food

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 6-64 years (both inclusive) at the time of signing informed consent~* Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months~* Body mass index (BMI) for children and adolescents (male and female) between the 3rd and 97th BMI percentile and for adults equal to or below 28.0 kg/m\^2~Exclusion Criteria:~* Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening~* Smoker (defined as a subject who is smoking at least one cigarette, cigar or pipe daily)~* Not able or willing to refrain from smoking and use of nicotine substitute products during the inpatient period

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- FIAsp (Type: EXPERIMENTAL): Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
- NovoRapid® (Type: ACTIVE_COMPARATOR): Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Remission and Joint Damage Progression in Early Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of rheumatoid arthritis (RA) \<=2 years; MTX naive or \<=10 mg/wk for \<=3 weeks. No dose within 3 months prior to informed consent.~* C-Reactive Protein (CRP) \>= 4.5 mg/L (after amendment)~* Rheumatoid factor or anti-cyclic citrullinated peptide antibody (anti-CCP) positive~* Tender joints \>=12 and swollen joints \>=10~Exclusion Criteria:~* Women and men who are not willing to use birth control~* Diagnosed with other rheumatic disease~* History of cancer within 5 years~* Active tuberculosis~* Treatment with another investigation drug within 28 days~* Active bacterial or viral infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ABA + MTX (Type: ACTIVE_COMPARATOR): abatacept 10 mg/kg intravenous (IV) + methotrexate
- Placebo (PLA) + MTX (Type: ACTIVE_COMPARATOR): placebo IV + methotrexate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have an available 8/8 human leukocyte antigen (HLA)-A, -B, -C, and -DRB1 matched-related or unrelated donor allogeneic hematopoietic peripheral blood stem cell graft.~* Acute myeloid leukemia, myelodysplasia, acute lymphoblastic leukemia, chronic myeloid leukemia, or myeloproliferative neoplasms requiring a matched allogeneic HSCT.~  * Acute Leukemia (AML or ALL) must be in complete remission defined as: \<5% marrow blasts with no morphologic evidence of leukemia, no peripheral blasts, marrow \>20% cellular, and peripheral absolute neutrophil count \>1000/µL (platelet recovery is not required).~ * Myelodysplasia (MDS) and chronic myeloid leukemia (CML): Must have \<5% marrow blasts.~ * Myeloproliferative neoplasms (MPN): Must have \<5% peripheral / marrow blasts.~* Adequate vital organ function:~  1. Left ventricular ejection fraction (LVEF) ≥ 45% by multi gated acquisition (MUGA) scan or ECHO~ 2. Forced expiratory volume at one second (FEV1), forced vital capacity (FVC), and adjusted diffusing lung capacity oxygenation (DLCO) ≥ 50% of predicted values on pulmonary function tests~ 3. Transaminases (AST, ALT) \< 2 times upper limit of normal values~ 4. Creatinine clearance ≥ 50 cc/min.~* Performance status: Karnofsky Performance Status Score ≥ 80%~* Donor eligibility: Eligible donors will include healthy sibling, relative or unrelated donors that are matched with the patient at HLA-A, B, C, and DRB1 by high resolution typing.~Exclusion Criteria:~* Active infection not controlled with appropriate antimicrobial therapy~* History of HIV, hepatitis B, or hepatitis C infection~* Anti-thymocyte globulin, alemtuzumab, bortezomib, or cyclophosphamide administered within 14 days before or planned to receive with HCT conditioning or as part of GVHD prophylaxis in the 14 days after HCT.~* Hypersensitivity to recombinant human IL-2~* Chronic lymphocytic leukemia, Hodgkin lymphoma, and non-hodgkin lymphoma are excluded as these malignancies may express the IL-2 receptor and pose a potential growth signal to any present disease.~* Sorror's co-morbidity factors with total score \>4

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GVHD Regimen (Type: EXPERIMENTAL): Graft versus host disease (GVHD) prophylaxis regimen IL-2 with Sirolimus and Tacrolimus after allogeneic hematopoietic cell transplant (HCT).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete